Atherosclerosis Drugs Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

Atherosclerosis Drugs Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Atherosclerosis Drugs Market is projected to register a CAGR of 2.2% during the forecast period (2022-2027).

In the COVID-19 pandemic, it was known that the lung was the primary organ to be affected; however, recent research indicates that SARS-CoV-2 infection can result in vascular illness. Chronic endothelial inflammation causes atherosclerosis by disrupting the delicate homeostasis of endothelial cells, which includes the hemostatic balance, inflammatory response, and vasomotor tone, among other features. The unregulated immunological environment created by the underlying endothelial dysfunction may be optimal for SARS-CoV-2 to cause a "cytokine storm" with severe clinical symptoms. Given that COVID-19 and atherosclerosis follow similar biological processes, targeted therapy has centered on preventing critical proteins from becoming activated. Drugs that target cytokines specifically are currently too expensive and far from being mass produced, despite the possibility that the results are positive. Statin treatment and other anti-platelet and anti-inflammatory medications, however, may act as a barrier against thrombotic problems following COVID-19. These abovementioned factors significantly drive the market in the pandemic conditions.

The major factor attributing to the growth of the market is the increase in the prevalence of atherosclerosis and cardiovascular diseases. According to the National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data updated in July 2022, about 697,000 people in the United States died from heart disease in 2020, that’s 1 in every 5 deaths. One person dies every 34 seconds in the United States from cardiovascular disease. The maximum incidences of cardiovascular diseases can be attributed to the sedentary lifestyle in developed countries. The sedentary lifestyle leads to a high prevalence of high blood pressure, high cholesterol, obesity, and high alcohol consumption, which together contribute to a high incidence of cardiovascular diseases. Therefore, the sedentary lifestyle leading to a high prevalence of cardiovascular diseases and increasing awareness of the treatment options are expected to drive the market studied. The prevalence and incidence of cardiovascular problems are increasing because of plaque formation, which is driving up the demand for new treatment alternatives. In June 2022, a novel polymer created by Ben-Gurion University (BGU) and the Sheba Medical Center is called an E-selectin-targeting polymer. By lowering and avoiding plaque development, it is a novel treatment for atherosclerosis that lowers the risk of ischemia, stroke, arterial thrombosis, and myocardial infarction. An intense statin therapy called Protein Convertase Subtilisin/Kexin type 9 (PCSK 9) lowers low-density lipoprotein cholesterol levels, which lowers the risk of coronary atherosclerotic plaque development. The development of the global market for atherosclerosis medications is projected to be fueled by new treatments for atherosclerosis.

The rising intake of cholesterol-lowering medications by patients to lessen artery blockages is responsible for this market expansion. Consumers who lead demanding, yet sedentary lifestyles tend to choose short meals, which is expected to open new revenue opportunities for the atherosclerosis drug industry. Additionally, global government initiatives have been essential in raising the standard of healthcare services and infrastructure, which has prompted pharmaceutical corporations to create efficient medicines for the treatment of a variety of disorders. Drugs for atherosclerosis have been selling well because of their efficiency and ease of accessibility thanks to efficient distribution systems.

However, low diagnostic rates and the availability of generic products are the factors expected to restrain the market growth during the forecast period. Due to several recalls of valsartan products made by various companies, the United States Food and Drug Administration approved a unique generic version of Diovan in March 2019 to close the high demand and limited supply gap of this crucial medication. After two months, Zydus Cadila declared that Chlorthalidone, a Pfizer-produced generic counterpart of Thalitone, had been approved.

Key Market TrendsCholesterol Lowering Medications Segment is Dominating the Atherosclerosis Drugs Market.

Cholesterol-lowering drugs include statins and fibrates. According to World Health Organization (WHO) 2022, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of total) and 29.7 million Disability-adjusted life years (DALYs), or 2% of total DALYS. Raised total cholesterol is a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. The dominant share of the segment is attributed to the increasing prevalence of cardiovascular disease and high cholesterol, and obesity globally. For instance, according to the World Health Organization 2022, an estimated 39 million children under the age of 5 were overweight or obese in 2020. Similarly, according to the World Health Organization (WHO) 2022, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. A heightened intake of energy-dense foods that are high in fat and sugars, and an upsurge in physical immobility due to the increasingly inactive nature of many forms of work, changing modes of transportation, and increasing urbanization are factors propelling the high cholesterol rates and ultimately boosting the segment growth.

Furthermore, the approval of novel cholesterol-reducing drugs is enhancing segment growth. For instance, the drugs, alirocumab (Praluent) and evolocumab (Repatha) belong to a new category of medications known as PCSK9 inhibitors which lower harmful LDL cholesterol values dramatically more than 50%. these types of novel treatment drugs boost segment growth. The increasing patient pool and increasing approvals of new drugs enhance the segment growth.

North America is Expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of cardiovascular diseases and atherosclerosis, and established healthcare infrastructure are some of the key factors accountable for its large share in the market. According to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data was updated in July 2022, 1 person dies every 34 seconds in the United States from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020, that’s 1 in every 5 deaths. Similarly, according to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data updated in July 2022, nearly 94 million United States adults aged 20 or older have total cholesterol levels higher than 200 mg/dL and around 28 million adults in the United States have total cholesterol levels higher than 240 mg/dL. As per the same source, around 7% of United States children and adolescents ages 6 to 19 have high total cholesterol. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. Hence, these aforementioned factors are expected to boost the market growth in the region.

Competitive Landscape

The Atherosclerosis drugs market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Pfizer Inc., AstraZeneca, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., Novartis AG, GlaxoSmithKline Plc, Bayer AG, Mylan N.V., Eli Lilly and Company

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.